DRP-selected stenoparib chasing platinum-resistant ovarian cancer approval, funded to mid-2028 — pivotal data will confirm or refute the DRP selection thesis

Allarity is a clinical-stage company developing stenoparib, a targeted cancer drug not yet approved, for platinum-resistant ovarian cancer in patients selected by a diagnostic test called DRP.

Phase 2 data presented at AACR 2026 showed extended overall survival in platinum-resistant ovarian cancer, strongest in patients with highest DRP scores, the first meaningful clinical validation of Allarity's patient-selection strategy. Whether that benefit reproduces in a pivotal, DRP-enriched population is the single question that determines whether stenoparib earns approval. The $20M Streeterville debt carries restrictive covenants and an 18-month repayment clock, adding structural pressure alongside an approval path that will rely on biomarker-enriched, single-arm or Phase 2-level data without a conventional Phase 3 comparator arm.